Evidence network for deaths_(OS)

1IMpower-130 (WT), 20191IMpower-130 (all population), 20191KEYNOTE-021, 20161KEYNOTE-189, 20182IMpower-150 (ABCP vs BPC WT), 2018 IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 20181IMpower-132 (WT), 01IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018pemetrexed plus platinplacebo plus SoCbevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelatezolizumab plus carboplatin plus nab-paclitaxelpembrolizumab and pemetrexed plus platinpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinatezolizumab plus carboplatin plus paclitaxeldirect evidencenetwork meta-analysis
T vs. C pemetrexed plus platinplacebo plus SoCbevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelatezolizumab plus carboplatin plus nab-paclitaxelpembrolizumab and pemetrexed plus platinpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinatezolizumab plus carboplatin plus paclitaxel
pemetrexed plus platin---NANANANANANANANANA
placebo plus SoCNA---NANANANANANANANA
bevacizumab plus carboplatin and paclitaxelNANA---NANANANANANANA
carboplatin plus nab-paclitaxelNANANA---NANANANANANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANA---NANANANANA
pembrolizumab and pemetrexed plus platinNANANANANA---NANANANA
pembrolizumab plus SoCNANANANANANA---NANANA
atezolizumab plus bevacizumab plus carboplatin plus paclitaxelNANANANANANANA---NANA
atezolizumab plus pemetrexed and platinNANANANANANANANA---NA
atezolizumab plus carboplatin plus paclitaxelNANANANANANANANANA---

pathologies: 307,165,163,176 - treatments: 744 result logic